Beclometasone/formoterol/glycopyrronium
Beclometasone/formoterol/glycopyrronium (trade name Trimbow) is an inhalable combination drug for the treatment of chronic obstructive pulmonary disease (COPD). In May 2017, the European Committee for Medicinal Products for Human Use recommended granting a marketing authorisation for the drug.[1]
Combination of | |
---|---|
Beclometasone dipropionate | Glucocorticoid |
Formoterol | Long-acting β2 agonist |
Glycopyrronium bromide | Antimuscarinic |
Clinical data | |
Trade names | Trimbow |
Routes of administration | Inhalation |
ATC code |
References
- "Summary of opinion for Trimbow" (PDF). European Medicines Agency. 23 May 2017.
Adrenergics, inhalants |
| ||||||||
---|---|---|---|---|---|---|---|---|---|
Glucocorticoids | |||||||||
Anticholinergics/ muscarinic antagonist | |||||||||
Mast cell stabilizers | |||||||||
Xanthines | |||||||||
Eicosanoid inhibition |
| ||||||||
Others/unknown | |||||||||
Combination products | |||||||||
|
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.